TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s TRUQAP™ (capivasertib) in combination with fulvestrant has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least…
Click here to view original post

Advertise With Biotech Networks